Open Access

BMP Signaling Is a Prognostic Marker in Patients With Colorectal Cancer and Associates With Frailty

SAWATA SHOHEI 1
SHIMIZU SHOTA 1
MATSUMI YOSHIAKI 2
KONO YUSUKE 1
KIHARA KYOICHI 1
YAMAMOTO MANABU 1
SAKAMOTO TERUHISA 1
UMEKITA YOSHIHISA 3
  &  
FUJIWARA YOSHIYUKI 1

1Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago, Japan

2Division of Chemical Biology, Technical Department, Tottori University, Yonago, Japan

3Division of Organ Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Yonago, Japan

Cancer Diagnosis & Prognosis Jul-Aug; 4(4): 416-423 DOI: 10.21873/cdp.10341
Received 16 March 2024 | Revised 13 July 2024 | Accepted 09 April 2024
Corresponding author
Shota Shimizu, MD, Ph.D., Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan. Tel: +81 859386567, Fax: +81 859386569, email: s.shimizu@tottori-u.ac.jp

Abstract

Background/Aim: Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β superfamily of ligands and have been shown to promote or suppress colorectal cancer (CRC) growth. Developing treatments that target BMPs is challenging due to their multiple roles, including involvement in the inflammatory response and nutritional status. The present study evaluated the prognostic value of BMP-4, which is believed to be highly expressed in CRC, and its correlation with inflammatory and nutrition statuses in patients with CRC. Materials and Methods: We analyzed BMP-4 expression in tumor tissues from 144 patients who underwent CRC surgery using immunohistochemistry and evaluated the relationship between BMP-4 levels and clinical outcomes. Results: Kaplan–Meier analysis revealed that patients with high expression levels of BMP-4 exhibited a shorter overall survival rate than those with low levels of expression. Multivariate analysis revealed that BMP-4 expression was an independent prognostic factor for overall survival and death from other diseases in CRC patients. Furthermore, high BMP-4 expression was significantly correlated with high C-reactive protein/Albumin ratio, sarcopenia, and osteopenia. Conclusion: BMP-4 is a significant prognostic factor in CRC, particularly in predicting death from other diseases, while also showing associations with inflammatory and nutritional statuses.
Keywords: Colorectal cancer, prognosis, BMP-4

The discovery of many biomarkers such as rat sarcoma viral oncogene homolog and B-Raf proto-oncogene, serine/threonine kinase and the development of drug therapies including molecular targeted drugs and immune checkpoint inhibitors for colorectal cancer (CRC) have been reported in recent years (1,2). Despite these advances, the cancer-related mortality rate of CRC is still higher compared with that of other cancers such as breast cancer and prostate cancer (3). Therefore, many clinical researchers have been searching for other biomarkers or mechanisms that might contribute to drug discovery.

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β (TGF-β) superfamily of ligands that bind to type I and type II serine-threonine kinase receptors and transduce signals through Smad and non-Smad pathways (4). Some studies showed that BMPs are highly expressed in CRC and identified a crosstalk between BMP signaling and epidermal growth factor receptor (EGFR) signaling, emphasizing the importance of the inhibition of BMP signaling for CRC growth suppression (5,6). In contrast, other studies showed that BMPs suppress the growth of CRC (7,8). Moreover, BMPs have been reported as tumor suppressors and tumor promoters in several cancers (9). Therefore, the roles of BMPs in CRC may be complex.

BMPs are divided into subgroups, including BMP-2/4, BMP-5/6/7/8, BMP-9/10, and the growth differentiation factor-5/6/7, by their structural similarities and ability to bind certain type I receptors (4). BMP-9 has been reported as a prognostic factor in CRC (10). Yokoyama et al. reported the correlation between BMP-4 and poor prognosis in an analysis using the GEO database (5). More recently, Zhuo et al. reported that BMP-4 has an anti-inflammatory role in inflammatory bowel disease (11), and Sartori et al. reported that decreased BMPs correlated with skeletal muscle wasting associated with cancer cachexia (12). Thus, BMPs can be a prognostic marker, but the development of treatment that targets BMP is too difficult.

The aim of this study was to investigate the prognostic value of BMP-4 expression in CRC and to evaluate the correlations between BMP-4 and inflammatory and nutritional status. BMP-4 and -7 are highly expressed in CRC (6), so we focused on BMP-4 among many BMP members.

Materials and Methods

Patients. This study included 144 patients who underwent colectomy for CRC at Tottori University Hospital, Yonago, Japan from January 2014 to December 2017 and who were diagnosed with pStage II or III CRC. Classification was performed using the 8th Edition of the Union for International Cancer Control TNM classification. Patients who underwent chemoradiation therapy before surgery, had a history of familial adenomatous polyposis, or had no cancer cells in the specimen because of previous endoscopic surgery were excluded. This study was approved by the institutional review board of Tottori University (No. 23A121).

Immunohistochemical analysis. Immunohistochemistry (IHC) was performed following standard protocols. Briefly, formalin-fixed, paraffin-embedded tissue was processed into 4-μm-thick sections. After deparaffinizing the tissue blocks, antigen retrieval was performed at 121˚C for 10 min in 10 mmol/l sodium citrate (pH 6.0). Endogenous peroxidase in the tissue sections was blocked by incubation with 3% hydrogen peroxide for 30 min, and non-specific protein binding was blocked with 10% Block-Ace (DS Pharma Biomedical, Osaka, Japan) for 30 min. Specimens were incubated with anti-BMP-4 antibody (ab124715, Abcam, Cambridge, UK, dilution of 1:200) at 4˚C overnight. The secondary antibody reagent was Histofine Simplestein MAX-P0 (Nichirei, Tokyo, Japan) and color development was performed using a DAB Peroxidase Substrate Kit (Vector Laboratories, Burlingame, CA, USA). Sections were counterstained with hematoxylin.

The expression of BMP-4 in CRC was assessed as the percentage of tumor cells with strongly positive staining, and a two-tiered discrimination using strong or weak staining was used. Tumors with >50% strongly positive cells were classified as high expression tumors, and those with ≤50% positive cells were classified as low expression tumors. Immunolabeling was evaluated by three investigators (S.S., S.S. and Y.U.); agreement was obtained in each case.

Inflammatory and nutritional markers. We collected the following blood test data from the patients’ records: serum Albumin (Alb) level (g/dl), C-reactive protein (CRP) level (mg/dl), and total peripheral blood lymphocyte, platelet, and neutrophil counts (cells/mm3). The CRP/Alb ratio (CAR) was calculated by dividing the serum CRP level by the serum Alb level. The neutrophil/ lymphocyte ratio (NLR) was calculated by dividing the peripheral neutrophil count by the peripheral lymphocyte count. The platelet/lymphocyte ratio (PLR) was calculated by dividing the peripheral platelet count by the peripheral lymphocyte count. The prognostic nutritional index (PNI) was calculated as follows: PNI=10 × serum Alb level + 0.005 × total peripheral lymphocyte count (13). We determined the bone mineral density (BMD) and skeletal muscle index (SMI) using preoperative plain Computed Tomography. BMD was measured in the trabecular bone by calculating the average pixel density within a circle of the mid-vertebral core at the bottom of the 11th thoracic vertebra (14). The Skeletal Muscle mass Index (SMI) was calculated by dividing the skeletal muscle area measured at the level of the third lumbar vertebra by the patient’s height (cm2/m2) (15). Preoperative osteopenia and sarcopenia were defined as low BMD and low SMI, respectively. The geriatric nutritional risk index (GNRI) was calculated as follows: 1.489 × serum albumin level (g/l) + 41.7 × body weight/ideal body weight (kg) (16). The cachexia index (CXI) was calculated as SMI × Alb/NLR (17). These data were collected within one month before surgery.

Statistical analysis. Differences in clinicopathological characteristics between two groups were evaluated using the chi-square test for categorical variables and the Mann–Whitney U-test for continuous variables. The Youden index was calculated using receiver operating characteristic (ROC) analysis to determine optimal cutoffs for NLR, PNI, PLR, CAR, GNRI, CXI, BMD, and SMI in the survival analysis. Survival curves were calculated using the Kaplan–Meier method. For the analysis of disease-specific survival (DSS), patients who died of causes other than CRC were considered lost to follow-up at the time of death. Differences between the curves were compared using the log-rank test. Cox proportional hazards models were used to evaluate prognostic factors for survival in univariate and multivariate analyses. All statistical analyses were performed using SPSS version 25.0 (IBM, Armonk, NY, USA). A p-value of <0.05 was considered statistically significant.

Results

BMP-4 is a significant prognostic factor in CRC. First, to investigate the expression levels of BMP-4 in CRC, we performed IHC for BMP-4 in 144 CRC tissues from pStage II-III patients. IHC analysis revealed that BMP-4 was overexpressed in tumor cells compared with adjacent normal tissues, and BMP-4 positive staining was predominantly observed in the cytoplasm of cancer cells (Figure 1A). Among the 144 patients, 85 (59%) had high BMP-4 expression. There was no correlation between BMP-4 expression and clinicopathological factors (Table I).

We next investigated whether BMP-4 expression was a prognostic factor for patients with CRC. Kaplan–Meier survival analysis showed that high BMP-4 expression was associated with poor prognosis in patients with pStage II-III. Both overall survival (OS) (p<0.001) and DSS (p=0.012) rates were significantly worse in patients with tumors harboring elevated BMP-4 expression (Figure 1B). While BMP-4 was not an independent prognostic factor for DSS, BMP-4 was an independent prognostic factor for OS (Table II). These results suggested that the percentage of patients who died from other diseases was higher in the BMP-4 high group. More deaths from other malignancies, pneumonia and heart failure were observed in the BMP-4 high group (Table III), and multivariate analysis revealed that BMP-4 was a significant risk factor for death from other diseases (Table IV).

Expression of BMP-4 is associated with prognostic inflammatory and nutritional markers. To evaluate survival prediction of several prognostic markers, such as preoperative NLR, PNI, PLR, CAR, GNRI, low SMI (for sarcopenia), low BMD (for osteopenia) and cachexia index, ROC curves were constructed, and the AUC values were compared. These markers reflect the patient’s inflammatory or nutritional status, and we reported the effectiveness of these markers to predict prognosis or recurrence in CRC (18,19). The AUC of CAR was the highest compared with that of other indicators (Table V). High BMP-4 expression was markedly correlated with high CAR, low SMI (sarcopenia) and low BMD (osteopenia) (Table VI).

Discussion

In this study, we evaluated the expression levels of BMP-4 in CRC tissues and demonstrated that elevated expression of BMP-4 was correlated with worse prognosis in patients with stage II/III CRC.

Several studies have examined whether the expression of BMPs or BMP signaling can be a prognostic marker in multiple cancers, including CRC, hepatocellular carcinoma, lung cancer, breast cancer, renal cell carcinoma, ovarian cancer, endometrial cancer, esophageal cancer, and prostate cancer (9). The conflicting roles of BMPs and BMP signaling pathways in cancer have also been reported. For example, in lung cancer, elevated serum BMP-2 levels were observed in many patients (20), but BMP-7-positive tumors were correlated with the absence of bone metastasis (21). In breast cancer, BMP-2/5/6/7 were detected in cancer tissues and the expression of the BMP type IA receptor was correlated with poor relapse-free survival (22); the expression of BMP antagonist was correlated with bone metastasis (23). BMP-7 expression in metastatic prostate cancer tissues was correlated with poor prognosis (24), and reduced BMP-2 expression in cancer tissue was correlated with recurrence (25). The expression of BMPs is detected in many organs, and their roles may vary between cancer sites and non-cancerous regions. Moreover, the influence of BMPs on the tumor environment may vary depending on the type of cancer. Additionally, the types of ligands that bind to BMP receptors, which transduce signals to Smad or non-Smad pathways, vary depending on the types of cancers.

In the present study, we found that BMP-4 expression was correlated with preoperative CAR (determined as the CRP/Alb ratio), sarcopenia and osteopenia in CRC. CRP is an acute-phase reactant regulated by inflammatory cytokines, particularly interleukin (IL)-6 (26). CAR is a serum-based inflammatory indicator linked to poor prognosis in septic patients and several malignancies (27-29). Sarcopenia is likely to be caused by increased protein catabolism, inflammatory reactions, metabolic abnormalities, and poor oral intake in cancer patients. Sarcopenia is associated with cancer cachexia (30). Osteopenia is associated with decreased bone mass and increased bone fragility (31). We previously mentioned that preoperative osteopenia is significant prognostic marker in gastric cancer patients (32). BMP signaling plays a key role in bone formation and homeostasis (33).

Previous studies showed that BMP signaling through Smad promotes muscle growth and protects skeletal muscle from denervation, which induces atrophy (34,35). Another report showed that BMP-4 enhances the expression of IL-6 and IL-8 (36). Sartori et al. showed that IL-6, which is induced by tumor-associated inflammation, induced noggin, a BMP antagonist, and blocked BMP signaling in muscle (12). This may be one possible mechanism for muscle wasting and cancer cachexia. With respect to osteopenia, Secondini et al. reported that Noggin induced by prostate cancer suppressed bone formation and osteoblast recruitment (37). Moreover, osteopenia may be associated with a poor prognosis because cytokines (e.g., parathyroid hormone-related protein, IL-1, and IL-6) derived from tumors activate the NF-kB pathway in osteoblasts or directly activate osteoclastogenesis (38,39). Therefore, BMP signaling may be correlated with inflammatory responses and muscle and skeleton frailty. In this study, CRC patients with high expression of BMP-4 were likely to die from other diseases, including pneumonia and heart failure, compared with patients with low expression. Previous studies showed that frailty is associated with susceptibility to or severity of pneumonia and heart failure (40,41). From these studies, we hypothesize that the inhibition of BMP signaling for tumor growth suppression may contribute to frailty of patients.

Study limitations. First, we did not examine the direct relationship between BMP-4 expression of CRC and prognostic inflammatory markers. Second, the cutoff value for defining each marker is not well established; therefore, we used cutoffs from previous reports or ROC analysis. Third, the number of patients in this study was small. Thus, a larger cohort study is necessary. Future studies on the mechanism by which BMPs affect the tumor microenvironment and the entire body are required.

Conclusion

Elevated BMP-4 may be a significant prognostic marker especially for non-CRC-related but frailty-related deaths. Our study indicates BMP-4 is associated with inflammatory and nutritional status in CRC. Future studies are required to elucidate the roles of BMP-4 in other organs in patients with CRC.

Conflicts of Interest

The Authors declare that they have no conflicts of interest in relation to this study.

Authors’ Contributions

Study conception and design: S. Sawata, Y. Matsumi and S. Shimizu; Acquisition of data: S. Sawata; Analysis and interpretation of data: S. Sawata and S. Shimizu; Drafting of manuscript: S. Sawata and S. Shimizu; Critical revision: Y. Fujiwara; Final approval of the article: all Authors.

Acknowledgements

The Authors would like to thank Gabrielle White Wolf, from Edanz (https://jp.edanz.com/ac), for editing a draft of this manuscript.

Funding

No funding was received for conducting this study.

References

1 Stintzing S Recent advances in understanding colorectal cancer. F1000Res. 7 F1000 Faculty Rev - 1528 2018. DOI: 10.12688/f1000research.14604.1
2 Yiu AJ & Yiu CY Biomarkers in colorectal cancer. Anticancer Res. 36(3) 1093 - 1102 2016.
3 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A & Bray F Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3) 209 - 249 2021. DOI: 10.3322/caac.21660
4 Miyazono K Kamiya Y & Morikawa M Bone morphogenetic protein receptors and signal transduction. J Biochem. 147(1) 35 - 51 2010. DOI: 10.1093/jb/mvp148
5 Yokoyama Y Watanabe T Tamura Y Hashizume Y Miyazono K & Ehata S Autocrine BMP-4 signaling is a therapeutic target in colorectal cancer. Cancer Res. 77(15) 4026 - 4038 2017. DOI: 10.1158/0008-5472.Can-17-0112
6 Shimizu S Kondo J Onuma K Coppo R Ota K Kamada M Harada Y Tanaka Y Nakazawa MA Tamada Y Okuno Y Kawada K Obama K Coffey RJ Fujiwara Y & Inoue M Inhibition of the bone morphogenetic protein pathway suppresses tumor growth through downregulation of epidermal growth factor receptor in MEK/ERK-dependent colorectal cancer. Cancer Sci. 114(9) 3636 - 3648 2023. DOI: 10.1111/cas.15882
7 Beck SE Jung BH Fiorino A Gomez J Rosario ED Cabrera BL Huang SC Chow JY & Carethers JM Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol. 291(1) G135 - G145 2006. DOI: 10.1152/ajpgi.00482.2005
8 Lombardo Y Scopelliti A Cammareri P Todaro M Iovino F Ricci-Vitiani L Gulotta G Dieli F de Maria R & Stassi G Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology. 140(1) 297 - 309.e6 2011. DOI: 10.1053/j.gastro.2010.10.005
9 Ehata S & Miyazono K Bone morphogenetic protein signaling in cancer; some topics in the recent 10 years. Front Cell Dev Biol. 10 883523 2022. DOI: 10.3389/fcell.2022.883523
10 Fan Y Guo L Zheng H Ji C Wang W & Sun H BMP-9 is a novel marker for colorectal tumorigenesis undergoing the normal mucosa-adenoma-adenocarcinoma sequence and is associated with colorectal cancer prognosis. Oncol Lett. 19(1) 271 - 282 2020. DOI: 10.3892/ol.2019.11125
11 Xie Z Zhou G Zhang M Han J Wang Y Li X Wu Q Li M & Zhang S Recent developments on BMPs and their antagonists in inflammatory bowel diseases. Cell Death Discov. 9(1) 210 2023. DOI: 10.1038/s41420-023-01520-z
12 Sartori R Hagg A Zampieri S Armani A Winbanks CE Viana LR Haidar M Watt KI Qian H Pezzini C Zanganeh P Turner BJ Larsson A Zanchettin G Pierobon ES Moletta L Valmasoni M Ponzoni A Attar S Da Dalt G Sperti C Kustermann M Thomson RE Larsson L Loveland KL Costelli P Megighian A Merigliano S Penna F Gregorevic P & Sandri M Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci Transl Med. 13(605) eaay9592 2021. DOI: 10.1126/scitranslmed.aay9592
13 Onodera T Goseki N & Kosaki G Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 85(9) 1001 - 1005 1984.
14 Sharma P Parikh ND Yu J Barman P Derstine BA Sonnenday CJ Wang SC & Su GL Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients. Liver Transpl. 22(8) 1092 - 1098 2016. DOI: 10.1002/lt.24458
15 Harimoto N Shirabe K Yamashita YI Ikegami T Yoshizumi T Soejima Y Ikeda T Maehara Y Nishie A & Yamanaka T Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 100(11) 1523 - 1530 2013. DOI: 10.1002/bjs.9258
16 Bouillanne O Morineau G Dupont C Coulombel I Vincent JP Nicolis I Benazeth S Cynober L & Aussel C Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 82(4) 777 - 783 2005. DOI: 10.1093/ajcn/82.4.777
17 Jafri SH Previgliano C Khandelwal K & Shi R Cachexia Index in advanced non-small-cell lung cancer patients. Clin Med Insights Oncol. 9 87 - 93 2015. DOI: 10.4137/CMO.S30891
18 Uejima C Saito H Tada Y Tanio A Murakami Y Yamamoto M Matsunaga T Fukumoto Y Tokuyasu N Takano S Sakamoto T Honjo S & Fujiwara Y The combination of prognostic nutritional indicator and serum carcinoembryonic antigen is useful in predicting postoperative recurrence in stage II colorectal cancer. Yonago Acta Med. 64(2) 176 - 183 2021. DOI: 10.33160/yam.2021.05.009
19 Yagyu T Yamamoto M Tanio A Hara K Sugezawa K Uejima C Kihara K Tatebe S Kurisu Y Shibata S Yamamoto T Nishie H Shiota S Saito H Naka T Sugamura K Katano K & Fujiwara Y Risk factors for recurrence in elderly patients with stage II colorectal cancer: a multicenter retrospective study. BMC Cancer. 22(1) 390 2022. DOI: 10.1186/s12885-022-09501-8
20 Choi YJ Kim ST Park KH Oh SC Seo JH Shin SW Kim JS & Kim YH The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients. Med Oncol. 29(2) 582 - 588 2012. DOI: 10.1007/s12032-011-9852-9
21 Liu Y Chen J Yang Y Zhang L & Jiang WG Μolecular impact of bone morphogenetic protein 7, on lung cancer cells and its clinical significance. Int J Mol Med. 29(6) 1016 - 24 2012. DOI: 10.3892/ijmm.2012.948
22 Pickup MW Hover LD Guo Y Gorska AE Chytil A Novitskiy SV Moses HL & Owens P Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis. Oncotarget. 6(26) 22890 - 22904 2015. DOI: 10.18632/oncotarget.4413
23 Tarragona M Pavlovic M Arnal-Estapé A Urosevic J Morales M Guiu M Planet E González-Suárez E & Gomis RR Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J Biol Chem. 287(25) 21346 - 21355 2012. DOI: 10.1074/jbc.M112.355834
24 Liu CH Tang WC Sia P Huang CC Yang PM Wu MH Lai IL & Lee KH Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance. Int J Med Sci. 12(1) 63 - 71 2015. DOI: 10.7150/ijms.9982
25 Tae BS Cho S Kim HC Kim CH Kang SH Lee JG Kim JJ Park HS Cheon J Oh MM & Kang SG Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis. Sci Rep. 8(1) 10748 2018. DOI: 10.1038/s41598-018-28566-9
26 Jones SA Novick D Horiuchi S Yamamoto N Szalai AJ & Fuller GM C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 189(3) 599 - 604 1999. DOI: 10.1084/jem.189.3.599
27 Fairclough E Cairns E Hamilton J & Kelly C Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond). 9(1) 30 - 33 2009. DOI: 10.7861/clinmedicine.9-1-30
28 Kinoshita A Onoda H Imai N Iwaku A Oishi M Tanaka K Fushiya N Koike K Nishino H & Matsushima M The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 22(3) 803 - 810 2015. DOI: 10.1245/s10434-014-4048-0
29 Saito H Kono Y Murakami Y Shishido Y Kuroda H Matsunaga T Fukumoto Y Osaki T Ashida K & Fujiwara Y Prognostic significance of the preoperative ratio of C-reactive protein to albumin and neutrophil–lymphocyte ratio in gastric cancer patients. World J Surg. 42(6) 1819 - 1825 2018. DOI: 10.1007/s00268-017-4400-1
30 Peixoto da Silva S Santos JMO Costa E Silva MP Gil da Costa RM & Medeiros R Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. J Cachexia Sarcopenia Muscle. 11(3) 619 - 635 2020. DOI: 10.1002/jcsm.12528
31 Tranquilli Leali P Doria C Zachos A Ruggiu A Milia F & Barca F Bone fragility: Current reviews and clinical features. Clin Cases Miner Bone Metab. 6(2) 109 - 113 2009.
32 Shimizu S Matsunaga T Sawata S Sakano YU Makinoya M Shishido Y Miyatani K Kono Y Murakami Y Hanaki T Kihara K Yamamoto M Tokuyasu N Takano S Sakamoto T Hasegawa T & Fujiwara Y Preoperative osteopenia is a risk factor for death in patients undergoing gastrectomy for gastric cancer. Anticancer Res. 43(8) 3665 - 3672 2023. DOI: 10.21873/anticanres.16548
33 Heubel B & Nohe A The role of BMP signaling in osteoclast regulation. J Dev Biol. 9(3) 24 2021. DOI: 10.3390/jdb9030024
34 Winbanks CE Chen JL Qian H Liu Y Bernardo BC Beyer C Watt KI Thomson RE Connor T Turner BJ McMullen JR Larsson L McGee SL Harrison CA & Gregorevic P The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J Cell Biol. 203(2) 345 - 357 2013. DOI: 10.1083/jcb.201211134
35 Sartori R Schirwis E Blaauw B Bortolanza S Zhao J Enzo E Stantzou A Mouisel E Toniolo L Ferry A Stricker S Goldberg AL Dupont S Piccolo S Amthor H & Sandri M BMP signaling controls muscle mass. Nat Genet. 45(11) 1309 - 1318 2013. DOI: 10.1038/ng.2772
36 Mano Y Yoshio S Shoji H Tomonari S Aoki Y Aoyanagi N Okamoto T Matsuura Y Osawa Y Kimura K Yugawa K Wang H Oda Y Yoshizumi T Maehara Y & Kanto T Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. J Gastroenterol. 54(11) 1007 - 1018 2019. DOI: 10.1007/s00535-019-01579-5
37 Secondini C Wetterwald A Schwaninger R Thalmann GN & Cecchini MG The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis. PLoS One. 6(1) e16078 2011. DOI: 10.1371/journal.pone.0016078
38 Jones DH Nakashima T Sanchez OH Kozieradzki I Komarova SV Sarosi I Morony S Rubin E Sarao R Hojilla CV Komnenovic V Kong YY Schreiber M Dixon SJ Sims SM Khokha R Wada T & Penninger JM Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 440(7084) 692 - 696 2006. DOI: 10.1038/nature04524
39 Roodman GD & Dougall WC RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev. 34(1) 92 - 101 2008. DOI: 10.1016/j.ctrv.2007.09.002
40 Iwai-Saito K Shobugawa Y Aida J & Kondo K Frailty is associated with susceptibility and severity of pneumonia in older adults (A JAGES multilevel cross-sectional study). Sci Rep. 11(1) 7966 2021. DOI: 10.1038/s41598-021-86854-3
41 Uchmanowicz I Młynarska A Lisiak M Kałużna-Oleksy M Wleklik M Chudiak A Dudek M Migaj J Hinterbuchner L & Gobbens R Heart failure and problems with frailty syndrome: Why it is time to care about frailty syndrome in heart failure. Card Fail Rev. 5(1) 37 - 43 2019. DOI: 10.15420/cfr.2018.37.1